Results 191 to 200 of about 1,106,843 (332)

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

Retracted: Blasting Law of Liquid CO2 Phase Change in Coal Mine Based on Numerical Simulation

open access: yesInternational Journal of Analytical Chemistry, 2023
International Journal of Analytical Chemistry
doaj   +1 more source

Evaluating the Greenness of Wine Analytical Chemistry: A New Metric Approach. [PDF]

open access: yesFoods
Thanasi V   +5 more
europepmc   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

open access: yesMolecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song   +11 more
wiley   +1 more source

Retracted: Prediction of Dissolved Oxygen Concentration in Sewage Treatment Process Based on Data Recognition Algorithm

open access: yesInternational Journal of Analytical Chemistry, 2023
International Journal of Analytical Chemistry
doaj   +1 more source

Analytical chemistry in front of the curtain! [PDF]

open access: yesAnal Bioanal Chem
Rosenberg E, Krska R.
europepmc   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy